Salzmann M, Enk A, Hassel J
Biomolecules. 2023; 13(3).
PMID: 36979464
PMC: 10046712.
DOI: 10.3390/biom13030529.
Yu Z, Zhao C, Hu S, Zhang H, Li W, Zhang R
RSC Adv. 2022; 11(41):25375-25380.
PMID: 35478925
PMC: 9037017.
DOI: 10.1039/d1ra04305f.
Hu Y, Song J, Wang Z, Kan J, Ge Y, Wang D
J Oncol. 2021; 2021:3586589.
PMID: 34712325
PMC: 8548170.
DOI: 10.1155/2021/3586589.
Olaoba O, Kadasah S, Vetter S, Leclerc E
Int J Mol Sci. 2020; 21(23).
PMID: 33256110
PMC: 7730603.
DOI: 10.3390/ijms21238989.
Allgower C, Kretz A, von Karstedt S, Wittau M, Henne-Bruns D, Lemke J
Cancers (Basel). 2020; 12(8).
PMID: 32722137
PMC: 7465620.
DOI: 10.3390/cancers12082037.
Tumor markers in oral cancer: A review.
Rajguru J, Mouneshkumar C, Radhakrishnan I, Negi B, Maya D, Hajibabaei S
J Family Med Prim Care. 2020; 9(2):492-496.
PMID: 32318370
PMC: 7113928.
DOI: 10.4103/jfmpc.jfmpc_1036_19.
Lipoblast-Like Morphology in a Uveal Melanoma with Delayed Metastasis to the Liver.
Toyama A, Bell W, Giubellino A, Li F
Ocul Oncol Pathol. 2020; 6(2):87-92.
PMID: 32258015
PMC: 7109438.
DOI: 10.1159/000501619.
S100 proteins as therapeutic targets.
Bresnick A
Biophys Rev. 2018; 10(6):1617-1629.
PMID: 30382555
PMC: 6297089.
DOI: 10.1007/s12551-018-0471-y.
S100B and LDH as early prognostic markers for response and overall survival in melanoma patients treated with anti-PD-1 or combined anti-PD-1 plus anti-CTLA-4 antibodies.
Wagner N, Forschner A, Leiter U, Garbe C, Eigentler T
Br J Cancer. 2018; 119(3):339-346.
PMID: 29950611
PMC: 6070917.
DOI: 10.1038/s41416-018-0167-x.
Emerging Biomarkers in Cutaneous Melanoma.
Eisenstein A, Gonzalez E, Raghunathan R, Xu X, Wu M, McLean E
Mol Diagn Ther. 2018; 22(2):203-218.
PMID: 29411301
DOI: 10.1007/s40291-018-0318-z.
S100A6 protein: functional roles.
Donato R, Sorci G, Giambanco I
Cell Mol Life Sci. 2017; 74(15):2749-2760.
PMID: 28417162
PMC: 11107720.
DOI: 10.1007/s00018-017-2526-9.
The evolution of S100B inhibitors for the treatment of malignant melanoma.
Hartman K, McKnight L, Liriano M, Weber D
Future Med Chem. 2012; 5(1):97-109.
PMID: 23256816
PMC: 3575173.
DOI: 10.4155/fmc.12.191.
Circulating serologic and molecular biomarkers in malignant melanoma.
Palmer S, Erickson L, Ichetovkin I, Knauer D, Markovic S
Mayo Clin Proc. 2011; 86(10):981-90.
PMID: 21964175
PMC: 3184027.
DOI: 10.4065/mcp.2011.0287.
Biomarkers in melanoma.
Gogas H, Eggermont A, Hauschild A, Hersey P, Mohr P, Schadendorf D
Ann Oncol. 2009; 20 Suppl 6:vi8-13.
PMID: 19617299
PMC: 2712589.
DOI: 10.1093/annonc/mdp251.
Sentinel node biopsy for early-stage melanoma: accuracy and morbidity in MSLT-I, an international multicenter trial.
Morton D, Cochran A, Thompson J, Elashoff R, Essner R, Glass E
Ann Surg. 2005; 242(3):302-11.
PMID: 16135917
PMC: 1357739.
DOI: 10.1097/01.sla.0000181092.50141.fa.
Tumor cell and circulating markers in melanoma: diagnosis, prognosis, and management.
Kounalakis N, Goydos J
Curr Oncol Rep. 2005; 7(5):377-82.
PMID: 16091200
DOI: 10.1007/s11912-005-0065-2.
Serum levels of S-100 protein and 5-S-cysteinyldopa as markers of melanoma progression.
Banfalvi T, Gilde K, Boldizsar M, Kremmer T, Otto S
Pathol Oncol Res. 1999; 5(3):218-22.
PMID: 10491021
DOI: 10.1053/paor.1999.0218.
The luminescence immunoassay S-100: a sensitive test to measure circulating S-100B: its prognostic value in malignant melanoma.
Bonfrer J, Korse C, Nieweg O, Rankin E
Br J Cancer. 1998; 77(12):2210-4.
PMID: 9649135
PMC: 2150414.
DOI: 10.1038/bjc.1998.368.
Benign schwannoma in the hepatoduodenal ligament: report of a case.
Nagafuchi Y, Mitsuo H, Takeda S, Ohsato K, Tsuneyoshi M, Enjoji M
Surg Today. 1993; 23(1):68-72.
PMID: 7681709
DOI: 10.1007/BF00309003.
Hypersensitivity to human brain S-100 protein in chronic alcoholics.
JANKOVIC B, Jakulic S, Horvat J
Clin Exp Immunol. 1982; 49(3):598-602.
PMID: 7172496
PMC: 1536733.
